Effective prevention in clinical practice may save human capital loss: Real-world evidence from Taiwan's National Health Insurance

被引:0
|
作者
Wang, Fuhmei [1 ,2 ]
Huang, Wen-Yen [2 ]
Chang, Yu-Tzu [3 ]
Yang, Szu-Chun [3 ]
Wang, Jung-Der [2 ,4 ]
机构
[1] Natl Cheng Kung Univ, Coll Social Sci, Dept Econ, Tainan, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, 1 Univ Rd, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Internal Med, Tainan, Taiwan
[4] Natl Cheng Kung Univ Hosp, Dept Occupat & Environm Med, Tainan, Taiwan
关键词
Lifetime productivity; Human capital; Lifetime employment duration; Prevention; QUALITY-OF-LIFE; CHRONIC KIDNEY-DISEASE; COST-EFFECTIVENESS; CARE; CANCER; BURDEN;
D O I
10.1016/j.jfma.2024.10.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose: Effective prevention could protect the health of the workforce, save human capital loss, and maintain employee productivity as well as economic growth. Methods: Using real-world data of patients with end-stage kidney disease (ESKD) and lung cancer, we multiplied their lifetime survival functions with employment ratios and working salaries to estimate the lifetime employment durations and earnings. They were compared with corresponding age-, sex-, and calendar year-matched referents to assess the differences in loss of lifetime employment duration and earnings. From 2000 to 2017, 83,358 patients with end-stage kidney disease (ESKD) were associated with 32-66% lifetime productivity losses. Similarly, we collected 24,904 incident cases of lung adenocarcinoma during 2011-2018 and estimated the potential savings in human capital due to early detection. Based on the evolving trends of ESKD incidence rates in Taiwan, we calculated the lifetime human capital losses of ESKD patients in GDP (gross domestic product) percentages during 2000-2020. Results: The aggregate lifetime productivity losses of ESKD in terms of GDP% varied between 0.000398% and 0.01% for male patients and between 0.0001% and 0.009% for female patients. The younger the patients, the bigger the losses in GDP%. Similarly, early detection of lung adenocarcinoma saved lives and productivity to some extent. Conclusions: Successful prevention of catastrophic illnesses at early stages would save the lifetime employment duration and productivity of the workforce. Future reform on the NHI could consider closer coordination between public health and healthcare organizations, focusing on effective prevention of diseases and complications to save productivity loss.
引用
收藏
页码:S251 / S258
页数:8
相关论文
共 50 条
  • [1] Real-world results of immune checkpoint inhibitors from the Taiwan National Health Insurance Registration System
    Hsieh, S-T
    Ho, H-F
    Tai, H-Y
    Chien, L-C
    Chang, H-R
    Chang, H-P
    Huang, Y-W
    Huang, J-J
    Lien, H-J
    Huang, L-Y
    Lee, P-C
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (21) : 6548 - 6556
  • [2] The real-world impact of National Institute for Health and Care Excellence's real-world evidence framework
    Duffield, Stephen
    Jonsson, Pall
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (11)
  • [3] REAL-WORLD RESULTS OF REIMBURSED IMMUNE CHECKPOINT INHIBITORS IN TAIWAN'S HEALTH INSURANCE SYSTEM
    Chien, L. C.
    Ying, Li H.
    VALUE IN HEALTH, 2022, 25 (12) : S468 - S468
  • [4] Is DTG+3TC effective and safe in clinical practice? Evidence from real-world data
    Punekar, Yogesh
    Parks, Daniel
    van Wyk, Jean
    de Ruiter, Annemiek
    Schroeder, Christina
    INFECTION, 2021, 49 (SUPPL 1) : S14 - S14
  • [5] Insights from Real-World Evidence on the Use of Inhalers in Clinical Practice
    Rubio, Myriam Calle
    Teppa, Pedro Jose Adami
    Hermosa, Juan Luis Rodriguez
    Carro, Miriam Garcia
    Martinez, Jose Carlos Tallon
    Rubio, Consolacion Riesco
    Cortes, Laura Fernandez
    Duenas, Maria Morales
    del Barrio, Valeria Chamorro
    Sanchez-del Hoyo, Rafael
    Aragon, Jorge Garcia
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
  • [6] Semaglutide in routine clinical practice: interesting news from real-world evidence
    Formoso, G.
    Baroni, M. G.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (08) : 1599 - 1600
  • [7] Real-World Evidence: Pharmacoepidemiology for Daily Clinical Practice—An Experience from Colombia
    Jorge Enrique Machado-Alba
    Andrés Gaviria-Mendoza
    Manuel E. Machado-Duque
    Luis Fernando Valladales-Restrepo
    Drugs - Real World Outcomes, 2020, 7 : 257 - 259
  • [8] Semaglutide in routine clinical practice: interesting news from real-world evidence
    G. Formoso
    M. G. Baroni
    Journal of Endocrinological Investigation, 2022, 45 : 1599 - 1600
  • [9] A brief introduction to research based on real-world evidence: Considering the Korean National Health Insurance Service database
    Ahn, Eun Kyoung
    INTEGRATIVE MEDICINE RESEARCH, 2022, 11 (02)
  • [10] Regional Difference of Liver Cancer in Japan: A Real-world Evidence Using the National Database of Health Insurance Claims
    Nakano, Masahito
    Kawaguchi, Machiko
    Nakano, Dan
    Sano, Tomoya
    Amano, Keisuke
    Nakamura, Toru
    Takahashi, Hirokazu
    Tarasawa, Kunio
    Fujimori, Kenji
    Kawaguchi, Takumi
    INTERNAL MEDICINE, 2025,